Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors

被引：0
|
作者：
Fernandez, E. [1 ]
Vernet, R. [2 ]
Charrier, E. [3 ]
Migliorini, D. M. [4 ]
Urwyler, M. [2 ]
Belkouch, M-C. [2 ]
Von Rohr, O. [5 ]
Saingier, V. [5 ]
Ancrenaz, V. [5 ]
Grandjean, N. [6 ]
Lafferma, E. [6 ]
Lavalliere, E. [6 ]
Rubin, O. [7 ]
Villard, J. [8 ]
Grogg, J. N. [9 ]
Mach, N. [10 ]
机构：
[1] HUG Hopitaux Univ Geneve, Dept Oncol, Geneva, Switzerland
[2] HUG Hopitaux Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland
[3] UNIGE Univ Geneve, Cell Based Immunotherapy Iab, Oncol, Ctr Med Univ CMU, Geneva, Switzerland
[4] Hop Univ Geneve HUG, Oncol, Geneva, Switzerland
[5] HUG Hop Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland
[6] HUG Hop Univ Geneve, Clin Res Unit, Oncol, Geneva, Switzerland
[7] HUG Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland
[8] Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland
[9] MaxiVax SA, R&D, Geneva, Switzerland
[10] HUG Hop Univ Geneve, Oncol, Geneva, Switzerland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.888
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762P
引用
收藏
页码：S891 / S891
页数：1
相关论文
共 50 条
  • [21] A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors
    Ghalib, Mohammad H.
    Pulla, Mariano Provencio
    Luken, Maria J. De Miguel
    de Juan, Virginia Calvo
    Chaudhary, Imran
    Hammami, M. Bakri
    Vikash, Sindhu
    Maitra, Radhashree
    Martinez, Sara
    Kahatt, Carmen
    Extremera, Sonia
    Fudio, Salvador
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (05) : 481 - 491
  • [22] PRELIMINARY SAFETY, PK/PD AND EFFICACY RESULTS FROM A FIRST-IN-HUMAN PHASE I/IIA CLINICAL TRIAL OF BNT411, A SYSTEMIC TOLL-LIKE RECEPTOR 7 AGONIST IN PATIENTS WITH SOLID TUMORS
    Symeonides, Stefan
    Mahalingam, Devalingam
    Chae, Young Kwang
    Calvo, Emiliano
    Miguel, Maria
    Arkenau, Hendrik-Tobias
    Garralda, Elena
    Galvao, Vladimir
    Mita, Alain
    Hassan, Hariz
    Baumhauer, Annette
    Voelker, Timo
    Kuehnle, Marie-Cristine
    Roesemann, Roman
    Strobl, Stefan
    Tuereci, Oezlem
    Sahin, Ugur
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A555 - A555
  • [23] First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors
    Wermke, Martin
    Holderried, Tobias A. W.
    Luke, Jason John
    Morris, Van K.
    Alsdorf, Winfried H.
    Wetzko, Katrin
    Andersson, Borje S.
    Wistuba, Ignacio I.
    Parra, Edwin R.
    Hossain, Mohammad B.
    Grund-Groeschke, Sandra
    Aslan, Katrin
    Satelli, Arun
    Marisetty, Anantha
    Satam, Swapna
    Kalra, Mamta
    Hukelmann, Jens
    Kursunel, M. Alper
    Pozo, Karine
    Acs, Andreas
    Backert, Linus
    Baumeister, Melissa
    Bunk, Sebastian
    Wagner, Claudia
    Schoor, Oliver
    Mohamed, Ali S.
    Mayer-Mokler, Andrea
    Hilf, Norbert
    Krishna, Delfi
    Walter, Steffen
    Tsimberidou, Apostolia M.
    Britten, Cedrik M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (07) : 1 - 18
  • [24] First-in-human (FIH) trial evaluating immune activation and safety of PIN-2 administered intravenously to patients with advanced solid tumors.
    Bier, Colin
    Millward, Michael
    Kotasek, Dusan
    Gorelick, Kenneth J.
    Goldberg, Joshua Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors
    Smith, Barry H.
    Parikh, Tapan
    Andrada, Zoe P.
    Fahey, Thomas J.
    Berman, Nathaniel
    Wiles, Madeline
    Nazarian, Angelica
    Thomas, Joanne
    Arreglado, Anna
    Akahoho, Eugene
    Wolf, David J.
    Levine, Daniel M.
    Parker, Thomas S.
    Gazda, Lawrence S.
    Ocean, Allyson J.
    CANCER GROWTH AND METASTASIS, 2016, 9
  • [26] RESULTS OF A FIRST-IN-HUMAN PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN ADVANCED SOLID TUMORS
    Shaw, A. T.
    Camidge, D. R.
    Felip, E.
    Sharma, S.
    Tan, D. S. W.
    Kim, D.
    De Pas, T.
    Vansteenkiste, J. F.
    Santoro, A.
    Liu, G.
    Goldwasser, M.
    Dai, D.
    Boral, A. L.
    Mehra, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 153 - 153
  • [27] Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial
    Noda, Toshiyuki
    Nishigaki, Kazuhiko
    Minatoguchi, Shinya
    CIRCULATION JOURNAL, 2020, 84 (07) : 1189 - +
  • [28] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
  • [29] First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts.
    Saleh, Mansoor
    Papadopoulos, Kyri
    Arabnia, Alireza
    Patnaik, Amita
    Stein, Robin M.
    Cattaneo, Federica
    Abbadessa, Giovanni
    Greenberg, Jonathan
    Warren, Stephen
    Tolcher, Anthony
    CANCER RESEARCH, 2013, 73 (08)
  • [30] Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas
    Shivaani Kummar
    Martin E. Gutierrez
    Lawrence W. Anderson
    Raymond W. Klecker
    Alice Chen
    Anthony J. Murgo
    James H. Doroshow
    Jerry M. Collins
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 917 - 923
12345